I certainly don't think that cf33 is dead.
If it is an effective treatment for just bile duct cancer, than that is worth heaps alone!
But even if imu shifts focus more to onCARlytics, that's ok.
NEU has become an asx biotech darling. But their initial focus was a drug called Glypromate. But that failed a phase 3, and hit the scrap heap. Then the focus was nnz2566 for traumatic brain injury, and again another failed clinical trial.
But neu have learnt and adapted, and are now a great success.
Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-151
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
-0.001(1.92%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.3¢ | 5.0¢ | $740.0K | 14.32M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1580775 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 683970 | 24 |
View Market Depth
| Last trade - 15.15pm 05/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |